Investors in BioAge Labs have been advised to contact BFA Law in connection with its investigation 76% of the company’s shares Investing.com
New York, New York–(Newsfile Corp. – January 4, 2025) – A leading securities law firm Bleichmar Fonti & Auld LLP announces investigation against BioAge Labs, Inc. (NASDAQ: BIOA) for possible violations of federal securities laws.
If you have invested in BioAge, we encourage you to get additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why is BioAge being researched?
BioAge Labs, Inc. is a clinical biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The Company’s lead product candidate, azelaprag, is an orally available small molecule apelin receptor (APJ) agonist designed to enhance weight loss.
During the relevant period, the company said that azelaprag was well tolerated by 265 people in eight phase 1 clinical trials and that after the company’s IPO it was “well equipped to advance our clinical programs[.]”
The stock drops as the truth is revealed
On December 6, 2024, BioAge announced that it had stopped its STRIDES Phase 2 trial of azelaprag, citing safety concerns, after hepatic transaminitis was observed in subjects receiving azelaprag. The company said the decision to stop the STRIDES phase 2 study of azelaprag “became clear” due to the “emerging safety profile of the currently tested doses[.]”
This news caused the company’s stock price to drop over 76%, from a closing price of $20.09 per share on December 6, 2024 to $4.65 per share on December 9, 2024.
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What can you do?
If you have invested in BioAge, you may have legal options and we encourage you to submit your information to the company.
All representation is on a contingency fee basis, at no cost to you. Shareholders are not responsible for any court costs or litigation expenses. The Company will seek court approval for all potential fees and costs.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. ISS SCAS named it one of the Top 5 Law Firms for Plaintiffs in 2023, Thompson Reuters named its attorneys Titans of the Plaintiffs Bar, and Thompson Reuters SuperLawyers. Among its recent notable successes, BFA recovered more than $900 million in value from Tesla (NASDAQ: ), Inc. board of directors (pending court approval), as well as $420 million from Teva Pharmaceutical (NYSE: ) Ind. Ltd.
For more information about BFA and its attorneys, visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Advertising of lawyers. Past results do not guarantee future results.
To view the original version of this press release, visit https://www.newsfilecorp.com/release/235856
